PULMONARY DRUGS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2022 to 2030)

The pulmonary drugs are used for treating the conditions affecting lungs. The pulmonary drugs are used from treating minor illnesses such as the common cold to cure long-term disorders such asthma. These agents are available in different forms such as oral tablets, oral liquids, and injections or inhalations. Inhalations deliver the medicine directly to the lungs, which can act directly on the lung tissues, minimizing systemic side effects.

Market Dynamics

The major factors driving growth of the pulmonary drugs market include increasing incidence of chronic respiratory diseases, tobacco smoking, and government and non-government initiatives. According to Center for Disease Control and Prevention (CDC), in 2015, 25 million people in the U.S. suffered from asthma that is 1 in 13 Americans were suffering from asthma. Under 18 years of age, 6.2 million people suffered from asthma. Annually asthma accounts for 14.2 million physician office visits and 1.8 million emergency visits. Moreover, the significant number of patent expiration of branded drugs, funding for research and development and launch of innovative products are expected to contribute as major factors in the market growth over the forecast period. For instance, in 2017, GSK received U.S. FDA approval for unique three-in-one inhaler named Trelegy Ellipta for chronic lung disease. Trelegy Ellipta combines three therapies into a single inhaler, thereby giving a new treatment option to the patients. However, a large undiagnosed population and side effects associated with the consumption of these drugs resulting into kidney problems leading to adverse outcomes are expected to limit the market growth.  

Key features of the study:

• This report provides in-depth analysis of pulmonary drugs market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2017 – 2025), considering 2017 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategy adopted by the leading players
• It profiles leading players in the global pulmonary drugs market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, and strategies, and future plans
• Key companies covered as a part of this study include Sanofi SA, Meda Pharmaceuticals, Circassia Pharmaceuticals Plc., AstraZeneca Plc., GlaxoSmithKline Plc., Mallinckrodt Pharmaceuticals Plc., Cheisi Farmaceuticals S.p.A, Zambon Company S.p.A, Alaxia SAS, and Merck Sharp & Dohme Limited
• Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
• The global pulmonary drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the pulmonary drugs market

Detailed Segmentation:

• Global Pulmonary Drugs Market, By Drug Class:
  • Inhaled Corticosteroids
  • Long Acting Beta-2 Agonists
  • Antihistamines
  • Vasodilators
  • Short Acting Beta-2 Agonists
  • Others
• Global Pulmonary Drugs Market, By Application:
  • Asthma & COPD
  • Allergic Rhinitis
  • Pulmonary Arterial Hypertension
  • Cystic Fibrosis
  • Others
• Global Pulmonary Drugs Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • E-Commerce
• Global Pulmonary Drugs Market, By Geography:
  • North America
    • By Country:
      • U.S.
      • Canada
  • Latin America
    • By Country:
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Europe
    • By Country:
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • By Country:
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • By Country:
      • GCC
      • Israel
      • Rest of Middle East
  • Africa
    • By Country:
      • South Africa
      • Central Africa
      • North Africa
• Company Profiles
  • Sanofi SA*
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Key Strategies
    • Recent Developments
  • Meda Pharmaceuticals
  • Circassia Pharmaceuticals Plc.
  • AstraZeneca Plc.
  • GlaxoSmithKline Plc.
  • Mallinckrodt Pharmaceuticals Plc.
  • Cheisi Farmaceutici S.p.A
  • Zambon Company S.p.A
  • Alaxia SAS
  • Merck Sharp & Dohme Limited

“*” marked represents similar segmentation in other categories in the respective section.